To this end, since amyloid deposition is common in cognitively impaired patients suffering from a brain disorder different from AD [67], with current data revealing 29% amyloid positivity in patients with non-AD brain disorders [68], p-tau isoforms are considered very useful for increasing the specificity for the identification of AD pathology. This evidence concerns the gene MAPT and Alzheimer disease.